drugset / Trial / NCT02285413

Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients

NCT02285413

Phase 2 Completed 54 enrolled Radboud University Medical Center
RandomizedSingle-groupOpen-labelTreatment

Summary

This is an exploratory study and the primary objective is the immunogenicity and feasibility of combined chemotherapy-DC vaccination. The secondary objectives are the toxicity and clinical efficacy. This study will provide important data on the immunological efficacy of DC immunochemotherapy.

Timeline

Start
2011-02
Primary completion
2015-10
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 50 mg/m2
Subject DCVax-L Vaccine Intravenous

Indications